LONG-TERM OUTCOMES OF LEDIPASVIR/SOFOSBUVIR (LDV/ SOF) FOR THE TREATMENT OF CHRONIC HEPATITIS C INFECTED (HCV) GENOTYPE 1 PATIENTS IN THE UK

被引：1
|
作者：
Guerra, I [1 ]
Marie, L. [2 ]
Cure, S. [1 ]
机构：
[1] OptumInsight, Uxbridge, Middx, England
[2] OptumInsight, Nanterre, France
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.2507
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PIN66
引用
收藏
页码：A675 / A675
页数：1
相关论文
共 50 条
  • [1] LONG-TERM OUTCOMES OF SOFOSBUVIR (SOF) FOR THE TREATMENT OF CHRONIC HEPATITIS C INFECTED (CHC) PATIENTS
    Cure, S.
    Guerra, I
    Dusheiko, G.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A357 - A357
  • [2] Long-term outcomes of sofosbuvir (SOF) for the treatment of chronic hepatitis C infected (CHC) patients
    Cure, Sandrine
    Guerra, Ines
    Granzow, Henrike
    Dusheiko, Geoffrey M.
    [J]. HEPATOLOGY, 2013, 58 : 747A - 747A
  • [3] A Decision-Analytic Markov Model To Evaluate The Health Outcomes of Ledipasvir/Sofosbuvir (LDV/SOF) for Patients with Chronic Hepatitis C (HCV) Genotype 1 (GT1) Infection
    Younossi, Zobair
    Saab, Sammy
    Ahmed, Aijaz
    Gordon, Stuart C.
    [J]. HEPATOLOGY, 2014, 60 : 1043A - 1043A
  • [4] Sofosbuvir (SOF) Suppresses Ledipasvir (LDV)-resistant Mutants during SOF/LDV Combination Therapy against Genotype 1b Hepatitis C Virus (HCV)
    Ashley N. Brown
    Lin Liu
    Jaime L. Rodriquez
    Lisa Zhao
    Layla Schuster
    Eric Li
    Gary P. Wang
    Michael N. Neely
    Walter Yamada
    George L. Drusano
    [J]. Scientific Reports, 7
  • [5] Sofosbuvir (SOF) Suppresses Ledipasvir (LDV)-resistant Mutants during SOF/LDV Combination Therapy against Genotype 1b Hepatitis C Virus (HCV)
    Brown, Ashley N.
    Liu, Lin
    Rodriquez, Jaime L.
    Zhao, Lisa
    Schuster, Layla
    Li, Eric
    Wang, Gary P.
    Neely, Michael N.
    Yamada, Walter
    Drusano, George L.
    [J]. SCIENTIFIC REPORTS, 2017, 7
  • [6] LEDIPASVIR (LDV)/SOFOSBUVIR (SOF) TREATMENT OF HEPATITIS C VIRUS (HCV) IS ASSOCIATED WITH REDUCTION OF SERUM APOLIPOPROTEIN LEVELS
    Younossi, Z.
    Elsheikh, E.
    Stepanova, M.
    Gerber, L.
    Nader, F.
    Brainard, D.
    McHutchinson, J. G.
    [J]. JOURNAL OF HEPATOLOGY, 2015, 62 : S599 - S599
  • [7] Declines in HBsAg Levels Observed during Treatment with Ledipasvir/Sofosbuvir (LDV/SOF) in Patients with Chronic Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Infection
    Liu, Chun-Jen
    Chuang, Wan-Long
    Sheen, I-Shyan
    Wang, Horng-Yuan
    Chen, Chi-Yi
    Tseng, Kuo-Chih
    Chang, Ting-Tsung
    Massetto, Benedetta
    Osinusi, Anu O.
    Camus, Gregory
    Jiang, Deyuan
    Zhang, Fangqiu
    Brainard, Diana M.
    McHutchison, John G.
    Hu, Tsung-Hui
    Hsu, Yao-Chun
    Lo, Gin-Ho
    Chu, Chi-Jen
    Chen, Jyh-Jou
    Peng, Cheng-Yuan
    Chien, Rong-Nan
    Chen, Pei-Jer
    [J]. HEPATOLOGY, 2017, 66 : 579A - 580A
  • [8] Real-World Retreatment of Sofosbuvir/Ledipasvir (SOF/LDV) Failures In Hepatitis C Virus Genotype 1 infection
    Pearlman, Brian
    Hinds, Andrew
    Perrys, Michael
    [J]. HEPATOLOGY, 2016, 64 : 478A - 478A
  • [9] Sofosbuvir (SOF) and Ledipasvir (LDV) Improves Patient-Reported Outcomes (PROs) in Patients Co-infected with Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)
    Younossi, Zobair M.
    Stepanova, Maria
    Sulkowski, Mark S.
    Naggie, Susanna
    Henry, Linda
    Hunt, Sharon L.
    [J]. HEPATOLOGY, 2015, 62 : 714A - 715A
  • [10] Sustained virologic response (SVR) in patients taking ledipasvir-sofosbuvir (LDV/SOF) and a proton pump inhibitor (PPI) in the treatment of chronic hepatitis C virus (HCV)
    Mangum, Jordan E.
    Pillai, Anjana A.
    Wedd, Joel P.
    Todd, Sarah B.
    [J]. HEPATOLOGY, 2016, 64 : 1004A - 1004A
12345